Chief Business Officer
Barry has diverse operating and strategic planning experience in both the medical device and biopharma sectors. Previously, he was Senior Director of Alliance Management at Macrolide Pharmaceuticals, a venture-backed startup developing novel antibiotics in the macrolide class of molecules. Prior to Macrolide, he held an Entrepreneur-in-residence role as a Blavatnik Fellow at Harvard Business School, where he co-founded and was Chief Business Officer of Symbal Therapeutics, a company developing a novel antibiotic for multi drug-resistant infections. The company partnered its lead preclinical-stage asset in 2016. Prior to that, he worked with global biotech firms of all sizes and development stages as a strategy consultant with IMS Consulting Group and concurrently in a sell-side transaction advisory role with IMS Health Capital. He began his career with Medtronic, where he worked as a product design engineer and later as a global clinical trial lead on a variety of vascular and cardiac rhythm implantable devices, several of which went on to capture significant market share. He holds a BS in biomedical engineering, magna cum laude, from Columbia, an MS in mechanical engineering from Stanford and an MBA from Harvard Business School.